A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably.
PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.
OBJECTIVES:
OUTLINE: This is a multicenter, prospective, cohort study.
Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.
Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests before the transplantation and 4 weeks after transplantation.
PROJECTED ACCRUAL: A total of 282 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
Planning to undergo treatment with any cisplatin-containing therapeutic regimen for cancer
Planning to enroll on clinical trial ACCL0431
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Little Rock, Arkansas 72205, United States
Palo Alto, California 95798, United States
Miami, Florida 33136, United States
Orlando, Florida 32803-1273, United States
Boise, Idaho 83712-6297, United States
Indianapolis, Indiana 46202, United States
Ann Arbor, Michigan 48109-0286, United States
Minneapolis, Minnesota 55404, United States
New York, New York 10032, United States
Charlotte, North Carolina 28233-3549, United States
Winston-Salem, North Carolina 27157-1096, United States
Portland, Oregon 97239-3098, United States
Sioux Falls, South Dakota 57117-5039, United States
Dallas, Texas 75390, United States
Spokane, Washington 99220-2555, United States